Jounce Therapeutics, Inc. Initial Public Offering
Davis Polk advised the lead book-running manager and representative of the underwriters in connection with its $101.9 million initial public offering of common stock of Jounce Therapeutics,…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Davis Polk Advises Affimed on Its $18 Million Offering of Shares
Davis Polk advised Affimed N.V. on its $18 million public offering of 10,000,000 of its common shares. The underwriters have a 30-day option to purchase an additional 1,500,000 shares. The…
Loxo Oncology, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $138 million SEC-registered offering of 4,450,500 shares of common stock of Loxo Oncology, Inc. The common stock is…
Sucampo Pharmaceuticals, Inc. $300 Million Convertible Senior Notes Offering
Davis Polk advised the sole book-running manager and initial purchaser in connection with a Rule 144A offering by Sucampo Pharmaceuticals, Inc. of $300 million aggregate principal amount of…
Davis Polk Advises Roche on Its $250 Million Cash Tender Offer
Davis Polk advised Roche Holdings, Inc. in connection with a cash tender offer for up to $250 million aggregate principal amount of its 7.00% notes due 2039.
Headquartered in Basel,…
Achaogen, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $100.9 million public offering of common stock of Achaogen, Inc. The common stock is listed onthe NASDAQ Global…
Yestar International Holdings Company Limited Placement of Shares
Davis Polk advised the sole placing agent in connection with the placing of 38,500,000 shares held by China Asset Management Co., Ltd. in Yestar International Holdings Company Limited for a…
Xencor, Inc. Follow-On Offering
Davis Polk advised the sole book-running manager in connection with the $126.5 million public offering of common stock of Xencor, Inc. The common stock is listed on the NASDAQ Global Market…
Evolent Health Convertible Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Evolent Health, Inc. of $125 million aggregate principal amount of its 2.00% senior convertible notes…
Abbott Laboratories $15.1 Billion Notes Offering
Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $2.85 billion aggregate principal amount of 2.350% notes due 2019, $2.85 billion…